Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Sierra Oncology, Inc. | d843782dex322.htm |
| EX-32.1 - EX-32.1 - Sierra Oncology, Inc. | d843782dex321.htm |
| EX-31.2 - EX-31.2 - Sierra Oncology, Inc. | d843782dex312.htm |
| EX-31.1 - EX-31.1 - Sierra Oncology, Inc. | d843782dex311.htm |
| EX-21.1 - EX-21.1 - Sierra Oncology, Inc. | d843782dex211.htm |
| EX-10.3 - EX-10.3 - Sierra Oncology, Inc. | d843782dex103.htm |
| EX-4.5 - EX-4.5 - Sierra Oncology, Inc. | d843782dex45.htm |
| EX-2.2 - EX-2.2 - Sierra Oncology, Inc. | d843782dex22.htm |
| 10-K - 10-K - Sierra Oncology, Inc. | d843782d10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-205693, 333-209897, 333-216392, 333-223253, 333-228263, and 333-229933 on Form S-8, and Registration Statement Nos. 333-225650 and 333-234554 on Form S-3 of our report dated March 3, 2020, relating to the consolidated financial statements of Sierra Oncology, Inc. and subsidiaries (the “Company”) appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2019.
| /s/ Deloitte & Touche LLP |
| Grand Rapids, Michigan |
| March 3, 2020 |